| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8466561 | Cytotherapy | 2018 | 9 Pages |
Abstract
The study demonstrates the safety and feasibility of pre-emptively manufacturing peptide pulsed ADV-specific cells for high-risk pediatric patients after transplantation and provides early evidence of clinical efficacy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Winnie Ip, Juliana M.F. Silva, Hubert Gaspar, Arindam Mitra, Shreenal Patel, Kanchan Rao, Robert Chiesa, Persis Amrolia, Kimberly Gilmour, Gul Ahsan, Mary Slatter, Andrew R. Gennery, Robert F. Wynn, Paul Veys, Waseem Qasim,